Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States. The company commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). It also develops KB803 for ocular complications of dystrophic epidermolysis bullosa; KB801 for neurotrophic keratitis; KB407, which is in Phase 1 clinical trials for treating cystic fibrosis; KB111 for Hailey-Hailey disease; KB707 for solid tumors; KB304 for dynamic wrinkles; KB707 that is in Phase 1/2 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.
| Business Activity | PASS |
| Debt Ratio | N/A |
| Cash Ratio | N/A |
| Receivables Ratio | N/A |
| Revenue Ratio (0.00%) | PASS |
| Overall | PASS |
$8.3B
7.15
0.495
9
$417.3M
$9.1M
+52.5%
1.20
10.23
0.2%
295
| Shares | Cost | Profit to Target | R:R |
|---|---|---|---|
| To Consensus ($322.78, 9 analysts) | |||
| 10 | $3,066.30 | +$161.50 (5%) | 0.4R |
| 50 | $15,331.50 | +$807.50 (5%) | 0.4R |
| 100 | $30,663.00 | +$1,615.00 (5%) | 0.4R |
- Elevated short interest (10.23 days to cover)
- Valuation stretched on forward earnings
A single score combining all analytical layers below. A is strongest, D is weakest.
How much could this ticker lose on a bad day? These metrics measure worst-case scenarios from historical data.
Based on 10,000 simulated price paths, here is the probability of where this ticker could be in 30, 60, and 90 days.
What direction is this ticker actually moving, filtered through noise? Is it speeding up or slowing down?
Classic chart signals that institutional traders monitor. Golden Cross is bullish, Death Cross is bearish.
Is this company financially sound? The Z-Score measures bankruptcy risk. The F-Score measures fundamental strength.
These tickers tend to move together (positive) or in opposite directions (negative). Useful for portfolio diversification.
| Ticker | Correlation |
|---|---|
| ARKG | 0.487 |
| CGON | 0.448 |
| IWM | 0.444 |
| HQH | 0.442 |
| XNCR | 0.438 |
| Ticker | Correlation |
|---|---|
| 4337.SR | -0.153 |
| STO.AX | -0.124 |
| WDS.AX | -0.119 |
| BAES.L | -0.113 |
| 4452.T | -0.112 |
Does this ticker have consistent patterns on certain days or months? Historical tendencies, not guarantees.
How does this ticker's recent performance compare to the entire universe? Ranked across 1, 3, 6, and 12-month returns.